Specifically, the data identified a 38 percent year-over-year reduction in self-reported marijuana use among eight graders, a 38 percent decline among 10th graders, and a 13 percent decrease among 12th graders.
Scientists reported: “Our results clearly demonstrate that NIDA cannabis samples are substantially genetically different from most commercially available drug-type strains and share a genetic affinity with hemp samples in several of the analyses.”
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses.
Federal officials have approved plans for the University of Mississippi to grow 2,000 kilograms (4,409 pounds) of cannabis to provide to investigators for clinical trial research.
Marijuana grown by the University of Mississippi for clinical research purposes is genetically divergent from strains of cannabis commercially available in retail markets, according to an analysis prepared by researchers at the University of Northern Colorado.
A bipartisan coalition of over two-dozen federal lawmakers, including House Judiciary Chairman Bob Goodlatte (R-VA) and Matt Gaetz (R-FL), are backing newly introduced legislation — The Medical Cannabis Research Act of 2018 — to facilitate federally-approved clinical trials involving cannabis. Passage of this act would end the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes by requiring the licensing of additional manufacturers.
Newly appointed head of the Drug Enforcement Administration (DEA), Chuck Rosenberg, says that marijuana is “probably” not as dangerous as heroin.
The director of the US National Institute on Drug Abuse (NIDA), Nora Volkow, believes that cannabidiol (CBD) – a nonpsychotropic cannabinoid – is “a safe drug with no addictive effects.”